key: cord-0073832-prmc7sf6
authors: Hsieh, Ching-Hung; Jian, Cheng-Zhe; Lin, Liang-In; Low, Guan-Sian; Ou, Ping-Yun; Hsu, Chiun; Ou, Da-Liang
title: Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
date: 2022-01-07
journal: Cancers (Basel)
DOI: 10.3390/cancers14020294
sha: afd5f2b327261f461243b10194e8b3509bfbb5ac
doc_id: 73832
cord_uid: prmc7sf6

SIMPLE SUMMARY: Immunotherapy is currently the backbone of new drug treatments for many cancer patients. CXC chemokine ligand 13 (CXCL13) is an important factor involved in recruiting immune cells that express CXC chemokine receptor type 5 (CXCR5) in the tumor microenvironment and serves as a key molecular determinant of tertiary lymphoid structure (TLS) formation. An increasing number of studies have identified the influence of CXCL13 on prognosis in patients with cancer, regardless of the use of immunotherapy treatment. However, no comprehensive reviews of the role of CXCL13 in cancer immunotherapy have been published to date. This review aims to provide an overview of the CXCL13/CXCR5 signaling axis to summarize its mechanisms of action in cancer cells and lymphocytes, in addition to effects on immunity and cancer pathobiology, and its potential as a biomarker for the response to cancer immunotherapy. ABSTRACT: Immune checkpoint inhibitors (ICIs), including antibodies that target programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), represent some of the most important breakthroughs in new drug development for oncology therapy from the past decade. CXC chemokine ligand 13 (CXCL13) exclusively binds CXC chemokine receptor type 5 (CXCR5), which plays a critical role in immune cell recruitment and activation and the regulation of the adaptive immune response. CXCL13 is a key molecular determinant of the formation of tertiary lymphoid structures (TLSs), which are organized aggregates of T, B, and dendritic cells that participate in the adaptive antitumor immune response. CXCL13 may also serve as a prognostic and predictive factor, and the role played by CXCL13 in some ICI-responsive tumor types has gained intense interest. This review discusses how CXCL13/CXCR5 signaling modulates cancer and immune cells to promote lymphocyte infiltration, activation by tumor antigens, and differentiation to increase the antitumor immune response. We also summarize recent preclinical and clinical evidence regarding the ICI-therapeutic implications of targeting the CXCL13/CXCR5 axis and discuss the potential role of this signaling pathway in cancer immunotherapy.

. Schematic representation of CXCL13/CXCR5 axis in T cells, B cells, and cancer cells, respectively. CXCL13 acts as a ligand that specifically binds to its receptor CXCR5. Upon activation, the GDP bound Gα protein subunit is replaced with a GTP molecule. This leads to the dissociation of Gαq or Gαi2 from the Gβ-Gγ dimer, mediating downstream signal activation. CXCL13 promotes chemotaxis in T cells and B cells. However, in cancer cells, CXCL13 promotes migration and inva- Figure 1 . Schematic representation of CXCL13/CXCR5 axis in T cells, B cells, and cancer cells, respectively. CXCL13 acts as a ligand that specifically binds to its receptor CXCR5. Upon activation, the GDP bound G α protein subunit is replaced with a GTP molecule. This leads to the dissociation of G αq or G αi2 from the G β -G γ dimer, mediating downstream signal activation. CXCL13 promotes chemotaxis in T cells and B cells. However, in cancer cells, CXCL13 promotes migration and invasion. The transcriptional factors involved in CXCR5 expression are diverse in T or B cells and cancer cells. In T cells, BCL6 regulates the CXCR5 expression via a repressor of repressor circuit. While in cancer cells, p53 regulates CXCR5 indirectly by suppressing NF-κB.

Transcriptional factor p52/RelB in the NF-κB pathway had been reported as a transcriptional factor of CXCL13 in macrophage [59] and B cells [60, 61] in mice lacking p52 or with a RelB defect in B-cell follicles and germinal centers formation [62] . NF-κB proteins are also key transcriptional factors of immune checkpoint PD-L1 [63] [64] [65] , suggesting that NF-κB would simultaneously control immune checkpoint blockade response and T/B cell recruitment. However, different transcriptional machinery controls the expression of CXCR5. In T cells, BCL6 activates CXCR5 expression by repressing repressor pathways [66] . Transcriptional factor E2A is directly bound to enhancer regions of CXCR5 to activate its expression [67, 68] . However, Id2/Id3 dampened CXCR5 expression by antagonizing E2A [68, 69] . BCL6 acts as a transcriptional repressor that directly inhibits Id2 expression in T cells, which, in turn, activates E2A activity and then stimulates CXCR5 expression [66, 70] . Interestingly, BCL6 and Blimp-1 are mutually exclusive and antagonize each other [71] . If Blimp-1 dominates BCL6 in this mutual competition, naïve CD4 + T cells will differentiate into Th1 cells that do not express CXCR5 [71] , in contrast, if upstream transcriptional factor T cell factor 1 (TCF-1) is triggered, naïve CD4 + T cells would differentiate into T FH and express CXCR5 [72] . This differentiation occurs because TCF-1 is a transcriptional factor that simultaneously suppresses Blimp-1 [73, 74] and activates BCL6 [75] . In CD8 + T cells, transcriptional regulators TCF-1, BCL6, E2A, Blimp-1, and Id2/Id3 also work collaboratively to shape CXCR5 expression with the same mechanism, as described in T FH cells [68] . In cancer cells, Mitkin et al. identified that p53 indirectly suppressed CXCR5 expression in the MCF breast cancer cell line. Silencing of p53 with shRNA significantly restored CXCR5 Cancers 2022, 14 , 294 5 of 20 expression in breast cancer cells. This was because p53 suppressed transcriptional factor NF-κB, which directly transactivates CXCR5 by interacting with the promoter region [76] . The expression of CXCR5 is regulated by the transcription factors BCL6 and Blimp-1. BCL6 drives the expression of CXCR5, whereas Blimp1 plays an inhibitory role. BCL6 and Blimp1 antagonize each other to regulate CXCR5 expression in T cells. [71] (Figure 1 ).

In addition to CXCL13/CXCR5, G ai2 is also involved in CXCR3 downstream signaling upon receiving its chemotaxis ligands CXCL9, CXCL10, and CXCL11. The CXCR3 has two variants, CXCR3A and CXCR3B. CXCL4, CXCL9, CXCL10, and CXCL 11 activate G ai in CXCR3A but not CXCR3B [77] . Of those G ai subunits, G ai2 is the most dispensable for T cells' CXCR5 response to CXCL9, CXCL10, and CXCL11 [78] .

The regulator of G protein signaling (RGS) acted as a GTPase-activating protein to terminate GPCR signaling by dephosphorylating the G α •GTP subunit [78, 79] . Silencing RGS1 restored chemotaxis of cytotoxic T cells and Th1 cells to enhance their infiltrating toward tumors. This process revealed that a G protein component, G α , is essential for the chemotaxis of cytotoxic T cells and Th1 cells [80] . The regulatory proteins of GPCR would be potential drug targets to revive anti-tumor activity.

CXCL13 is a chemoattractant that selectively interacts with its receptor, CXCR5, to promote the migration of CXCR5 + cells toward high CXCL13 concentration areas. CXCL13 was originally identified as B cell attracting chemokine 1(BCA-1) and was shown to act on CXCR5 + B cells to induce chemotaxis and Ca 2+ mobilization [81] . In lymph nodes, the CXCL13/CXCR5 axis is essential for homing B lymphocytes to lymphoid tissue, and CXCL13/CXCR5 deficient mice show the disrupted localization of B cells [81] .

CXCL13 recruits B cells to tumors, where they form tertiary lymphoid structures (TLSs) [82] . TLSs are similar to secondary lymphoid organs on the cellular, morphological, and molecular levels, and TLSs are considered with good prognostic markers, commonly associated with better survival rates. However, the mechanisms underlying TLS development remain unclear. Rodriguez et al. found that the organization of cancer-associated fibroblasts into reticular networks depends on tumor necrosis factor receptor signaling, which acts as a lymphoid tissue organizer [83] . Cancer-associated fibroblasts secrete CXCL13 to recruit CXCR5 + B cells expressing lymphotoxin-α1β2, which expands TLSs in the tumor microenvironment. Moreover, CD8 + T cells mediate cancer-associated fibroblast organization, serving as an inducer of lymphoid structures to drive the formation of TLSs.

CXCR5 + T cells were originally defined as CD4 + memory-like T cells, which function to assist B cells with antibody production. The colocalization of CXCL13, CXCR5 + T cells, and B cells was detected in the follicular mantle zone. A unique subset of T cells that assist in B cell function was identified as T FH cells [84] . High levels of BCL6 drive T FH differentiation, and Blimp-1 is able to block T cells from differentiating into T FH cells [71] .

T FH cells are the major CXCL13-producing cells in the lymphoid structure. In tumor microenvironments, tumor-infiltrating CXCL13-producing T FH cells may be involved in promoting local B cell localization, differentiation, and maturation [85] . An activated germinal center of B cells then contributes to the formation of TLSs in tumors. Gu-Trantien et al. first observed CXCL13 producing T FH cells in breast cancer and found that the T FH signature strongly predicted a positive clinical outcome in breast cancer [86] . Naïve CD4 + T cells differentiate into T helper 1 (Th1)-oriented T FH cells that produce CXCL13 in tumor microenvironments after being primed by antigen-presenting cells in the lymph node [87, 88] . The balance of T FH /Th1 differentiation from precursor cells is determined by the competitive expression of Bcl6 and T-bet [71, [89] [90] [91] . Further investigation revealed that tumor-infiltrating T FH cells produce CXCL13 to attract CXCR5 + CD8 + T cells and CXCR5 + B cells toward the germinal centers within the TLS, where both T cells and B cells are primed, reinforcing their cytotoxic capacity against cancer cells [92] . These studies indicate that BCL6-dominant signaling promotes CXCL13 expression in T FH cells [93] . Another subset of T FH cells, which were PD-1 hi CXCR5 − CD4 + T cells that expressed CXCL13, did not show elevated BCL6 expression.

In addition to T FH cells, there are several CXCL13 producing cells in lymphoid tissue and would secrete CXCL13 to chemoattract cells that express CXCR5. Denton et al. identified pulmonary fibroblasts as CXCL13-producing cells induced by Type I interferon (Type I IFN) during Influenza A virus transfection, which facilitate the recruitment of CXCR5 + B cells and T cells to the lungs to generate pulmonary germinal centers [94] .

Antigen-specific CD4 + T cells mediate and coordinate immune cell functions in antitumor activities. Although the effects of ICI have been thoroughly explored in CD8 + T cells, the roles played by CD4 + T cells in response to ICI remain poorly understood. Balança et al. studied exhausted CD4 + T cells in head and neck, cervical, and ovarian cancers [95] . With exhausted CD4 + T cells defined as those cells presenting high PD-1 and CD39 levels, which were found to secrete CXCL13 and express the transcription factor thymocyte selection-associated high mobility group box (TOX). The transcription factor SRY-box transcription factor 4 (SOX-4) mediates CXCL13 production on CD4 + T cells, enriching transforming growth factor-β (TGF-β) and reducing IL-2 expression [96] . Similar to CXCL13 + exhausted CD8 + T cells, exhausted CD4 + T cells recruit B cells and promote the formation of TLS, suggesting a good response to immunotherapy and indicating a crucial role for CD4 + T cells in mediating the functions of various immune cells.

Cytotoxic CD8 + T cells are the strongest effectors, playing important roles in the anticancer immune response. When examining the CXCL13/CXCR5 axis, Workel et al. found that TGF-β dependent CD103 + CD8 + tumor-infiltrating T cells represent an important CXCL13 resource [97] . When TGF-β receptors are inhibited, CXCL13 signaling is abrogated. CXCL13 + CD103 + CD8 + tumor-infiltrating T cells are associated with B cell recruitment, TLS formation, and neoantigen burden. Additionally, Thommen et al. also found that PD-1 high CD8 + tumor-infiltrating T cells produce more CXCL13 than PD-1 -CD8 + T cells in non-small-cell lung cancer (NSCLC) [34] . They also observed that CXCL13 recruited other CXCR5-expressing immune cells and induced the formation of TLSs in NSCLC. PD-1 high CD8 + tumor-infiltrating T cells are enriched inside the TLS, and their presence successfully predicts the response to anti-PD-1 and is positively correlated with overall survival.

In chronic hepatitis B infection, Li et al. found that higher levels of CXCL13 facilitate the recruitment of CXCR5 + CD8 + T cells to liver tissue in patients, which is associated with a favorable response to antiviral drug treatment [98] . CXCR5 + CD8 + T cells secrete hepatitis B virus (HBV)-specific cytokines, such as IL-2, IFN-γ, IL-17, and IL-21. The subset of CD8 + T cells is partially exhausted but not dysfunctional and is involved in controlling the viral infection load. Strikingly, the adoptive transfer of CXCR5 + CD8 + T cells to an HBV mouse model resulted in a significant decrease in HBV antigen expression. Finally, they found that B cell-deficient mice have a lower frequency of CXCR5 + CD8 + T cells and decreased the HBV-specific IFN-γ + CXCR5 + CD8 + T cells in the blood and liver. These data demonstrated that B cells are required for CXCR5 + CD8 + T cells, contributing to the functions and activities of CXCR5 + CD8 + T cells.

In classical Hodgkin lymphoma, Le et al. identified a special CD8 + T cell subset expressing CXCR5 and an inducible T cell costimulator (ICOS) [99] . This subset was functionally similar to T FH cells, with low CCR7 expression and high levels of BCL6, PD-1, CD200, and OX40 expression. In addition, these cells displayed poor cytotoxic function and low interferon-secretion and produced IL-4, IL-21, and CXCL13, similar to CD4 + T FH cells. Gene profiling analyses demonstrated that CXCR5 + ICOS + CD8 + T cells are significantly similar to CD4 + T FH cells and are involved in the generation of lymphoma tumors with residual germinal centers. Overall, CD8 + T cell differentiation pathways are functionally similar to those involved in CD4 + T FH cell differentiation in Hodgkin lymphoma. Follicular dendritic cells represent the primary cellular source of cytokines in lymphoid organs [100] . Previous research has identified that various dendritic cell subsets are able to secrete CXCL13, playing an important role in the establishment of interactions between lymphocytes and dendritic cells [101] . Additionally, CXCL13 serves as a plasma biomarker that reflects germinal center activity [102] . Follicular dendritic cells represent the primary source of CXCL13 expression in reactive tonsils and lymph nodes located in the B cell zone. Moreover, dysplastic and neoplastic follicular dendritic cells are able to secrete CXCL13 to recruit lymphocytes to areas of dense inflammatory infiltration [100] . Overall, dendritic cells secrete CXCL13 to recruit CXCR5 + lymphocytes, orchestrating the immune response in lymphoid tissues.

We summarize prior findings regarding CXCL13 and CXCR5 expression. CD8 + and CD4 + T cells, cancer-associated fibroblasts, cancer cells, and dendritic cells are able to secrete CXCL13, and CD8 + and CD4 + T cells, B cells, and cancer cells express CXCR5 ( Figure 2 ). Increasing research has reported the detection of CXCL13 in the tumor microenvironment of many different types of cancer [103] [104] [105] [106] [107] [108] [109] . When the cancer microenvironment is enriched in CXCL13, the recruitment of CXCR5-expressing leukocytes to the tumor microenvironment increases. B cells are recruited by CXCL13 to promote TLS formation in the tumor microenvironment ( Figure 3 ). Previous studies have correlated TLS formation with better prognosis among patients with cancer [110] [111] [112] [113] ; therefore, treatments that promote the development of TLSs represent potential therapeutic strategies.

Cancers 2022, 14, x FOR PEER REVIEW 7 of 20 ment is enriched in CXCL13, the recruitment of CXCR5-expressing leukocytes to the tumor microenvironment increases. B cells are recruited by CXCL13 to promote TLS formation in the tumor microenvironment ( Figure 3 ). Previous studies have correlated TLS formation with better prognosis among patients with cancer [110] [111] [112] [113] ; therefore, treatments that promote the development of TLSs represent potential therapeutic strategies. ment is enriched in CXCL13, the recruitment of CXCR5-expressing leukocytes to the tumor microenvironment increases. B cells are recruited by CXCL13 to promote TLS formation in the tumor microenvironment ( Figure 3 ). Previous studies have correlated TLS formation with better prognosis among patients with cancer [110] [111] [112] [113] ; therefore, treatments that promote the development of TLSs represent potential therapeutic strategies. 

Immune checkpoint blockade therapy has been hugely successful with effective results in many cancer types [114] [115] [116] , acting through reinforcement of T cell function and improving the cytotoxic capacity against cancer cells [1] . In this section, we summarize existing research examining the contributions of CXCL13/CXCR5 to immunotherapy in preclinical models (Table 1) . sequencing, quantitative reverse transcriptase PCR (qPCR), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and Western blotting methods. They identified the recruitment of CXCR5 + CD8 + T cells by CXCL13. Additionally, anti-PD-1 blockade and recombinant IL-21 therapy can promote the secretion of IFN-γ from CXCR5 + CD8 + T cells in patients with HBV. In an HBV mouse model, CXCR5 + CD8 + T cells would inhibit hepatitis B surface antigen (HBsAg) expression, which was not observed in response to CXCR5 -CD8 + T cells. Anti-PD-1 and IL-21 treatment strengthen the function of immune cells involved in HBV clearance or the attack of cancer cells.

Rodriguez et al. studied cancer-associated fibroblasts to determine the effects of TLSs in a melanoma and colon adenocarcinoma mouse model [83] . Anti-PD-L1 and a combination of anti-PD-1 and anti-CTLA4 both increase the formation of TLSs in the tumor microenvironment, resulting in reduced tumor growth, and increased T cell recruitment to the tumor, as indicated by the formation of discrete T cell and B cell zones. They observed CXCL13 expression on cancer-associated fibroblasts, as assessed by immunofluorescence and real-time PCR. Finally, they found that immunotherapy increased the tumor-associated TLS size and number, which was associated with reduced cancer growth.

Balança et al. studied the role of CD4 + T cells in immunotherapy during the attack on cancer cells [95] . They applied single-cell RNA sequencing analysis to patient-derived samples of head and neck, cervical, and ovarian cancer to detect the expression of transcription factor TOX and the chemokine CXCL13. They found that anti-PD-1 therapy promoted the functional activity of exhausted CD4 + T cells, promoting dendritic cell maturation and CD8 + T cell proliferation. Exhausted CD4 + T cells also play important roles in regulating and coordinating immune cells in the attack on cancer cells after immunotherapy treatment.

Yang et al. analyzed the influence of CXCL13 on the ICI response in an ovarian cancer mouse model [117] . They identified different immune cell subsets in samples from patients with high-grade ovarian cancer that were able to secrete CXCL13. High levels of CXCL13 expression resulted in increased lymphocytes infiltration in the tumor, as assessed by immunofluorescence. Conclusively, anti-PD-1 combined with CXCL13 treatment is associated with a better treatment response than anti-PD-1 alone in a mouse model of ovarian cancer.

Zhang et al. combined the inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6i) with anti-PD-1 therapy and examined the synergistic effects in an ovarian cancer mouse model [119] . PCR and cytokine array methods were applied to detect cytokine and chemokine levels, which revealed that ID8 ovarian cancer cells secrete higher levels of CXCL10 and CXCL13 after CDK4/6i treatment resulting in increased lymphocytes infiltration in the tumor microenvironment. Combination treatment is associated with a better response and more active function among CD8 + and CD4 + T cells than anti-PD-1 or CDK4/6i alone, and the synergistic antitumor effects were dependent on the activities of B cells and CD8 + T cells.

B cells play important roles in the results of immunotherapy. Cabrita et al. reported that TLSs influence the immunotherapy response of melanoma, showing that the cooccurrence of CD8 + T cells and CD20 + B cells can predict the response to ICI therapy in patients with metastatic melanomas [118] . CXCL13, CXCR5, CD8 + T cells, and CD20 + B cells colocalized in melanoma samples obtained from patients using immunofluorescence staining, which revealed the TLS formation in these tumors. Moreover, gene expression associated with TLS formation was able to predict the clinical outcomes of immunotherapy. Without TLS formation, a dysfunctional molecular phenotype can be observed, with adverse effects on immunotherapy outcomes. TLSs play critical roles in influencing the response of the tumor microenvironment to ICI therapy, and therapeutic strategies that induce TLSs' formation might improve the efficacy of immunotherapy.

CXCL13 has been identified as an exhaustion marker in previous research [120, 121] . Studies have increasingly identified immunotherapy as being positively correlated with exhausted immune cells [122] [123] [124] , including our research results for HCC [125] . The increased expression of exhaustion markers in the tumor microenvironment is an indicator of increased immune cell infiltration, which suggests a good response to immunotherapy. Bassez et al. identified several genes that were able to predict a better immune response to anti-PD-1 treatment associated with CXCL13 [126] . CXCL13 expression at high levels corresponds with T cells expansion after anti-PD-1 treatment for breast cancer, which is associated with a good response to immunotherapy.

Research continues into understanding why some subsets of patients respond to immunotherapy, but others do not respond. The heterogenicity of tumor cells and immune cells is a very important issue, which brings about different immunotherapy efficacy regardless of tumor types. The study divided cancer patients into two groups [126] . One group had expanding T cells, and the other had non-expanding T cells following anti-PD-1 therapy. The results demonstrated that CXCL13 expression on T cells is associated with the expansion of T cells, which implies that one subset of patients has a good response after immune checkpoint inhibitors treatment. The research sheds light on the exploration of the heterogenicity of immunotypes as well as associated genes for immunotherapy response.

We summarize the effects of CXCL13 and CXCR5 expression on preclinical models of the immunotherapy response. TLSs play critical roles in influencing the response to immune checkpoint blockade in the tumor microenvironment. Anti-PD-1 antibodies in the tumor microenvironment activate CD8 + T cells, and CD4 + T cells mediate CD8 + T cell proliferation and dendritic cell maturation (Figure 3 ). CXCL13 expression recruits additional immune cells to infiltrate the tumor environment to attack cancer cells following immunotherapy treatment.

Immune checkpoint blockade can regulate tumor progression. Compared with chemotherapy, ICI therapy has a superior duration of response (20.4 months vs. 6.3 months) [127, 128] . However, only 15-20% of patients benefit from immunotherapy [128] and the identification of biomarkers able to predict therapeutic response to ICI. Recently, some biomarkers were identified that were able to accurately predict the response of cancer patients to PD-1 blockade. Le et al. proposed that patients with mismatch repair deficiencies have a higher response rate to pembrolizumab treatment than patients with proficient mismatch repair processes [129] . In this section, we summarize clinical trials and research linking the CXCL13/CXCR5 axis with the ICI response in patients ( Table 2) .

Gu-Trantien et al. analyzed CD4 + T cells in tumor tissues by profiling gene signatures. They identified T FH-related genes, such as CD200, CXCL13, ICOS, and PD-1, that were overexpressed in infiltrated tumors. They divided patients' tumors into those with a high level of CD4 + tumor-infiltrating lymphocytes (TILs) and those with minimal infiltration [86] . Among patients with a high level of TILs, CXCL13 was the most highly overexpressed gene. IHC staining indicated that CXCL13 was not expressed in tumor cells but was detected intensively in TLSs and CD4 + T FH cells. Clinical correlations with CXCL13 were performed by investigating the disease-free survival (DFS) of 794 breast cancer patients, which revealed that CXCL13 expression was positively correlated with DFS in breast cancer, especially in the human epidermal growth factor 2 (HER2 + ) group. The authors also analyzed a cohort of 996 patients with breast cancer who received neoadjuvant chemotherapy, which showed that CXCL13 expression was highly correlated with a complete response in HER2 + patients. High levels of baseline CXCL13 + T cells predict favorable response to anti-PD-L1 plus nab-paclitaxel combination therapy [131] .

Anti-PD-L1, Anti-PD-1, Anti-CTLA4

Single-cell RNA-seq ATAC-seq n = 1008 Favorable CXCL13 expression is a marker of clonal neoantigen-specific CD8 + TILs that selectively expresses in CPI responders ("CR/PR"). [132] . [131] . Twenty-two patients with late-stage TNBC were enrolled in this cohort, divided into two groups with equal numbers. Patients in one group were treated with paclitaxel, whereas the other group received paclitaxel plus atezolizumab. After 4 weeks, tumor biopsies and peripheral blood cells were collected from both groups. TILs were collected and analyzed by single-cell RNA-sequencing, single-cell ATAC-sequencing, and TCRsequencing. In this cohort, the authors developed two indexes to associate immune subsets with clinical benefits in TNBC: the predictive index (Pi) and the therapeutic index (Ti). The Pi correlated the compositions of TIL subsets with changes in tumor volume, whereas the Ti correlated between TIL subsets dynamics with tumor volume changes. They identified B cells as being the most predictable subset for predicting the response to immune checkpoint blockade in the Pi analysis, whereas T cells were the most predictable subset to predict immune checkpoint blockade in the Ti analysis, indicating a functional change in T cells during ICI therapy. The authors clustered T cells using a high-resolution T cell map, which identified expanded CXCL13 + CD8 + and CXCL13 + CD4 + populations in patients who responded to paclitaxel plus atezolizumab but not patients who did not respond to treatment. Furthermore, the analysis of CXCL13 + CD8 + T cells using a single-cell assay for transposase-accessible chromatin using sequencing (ATAC-seq) showed that CXCL13 + CD8 + cells had more accessible chromatin regions in the IFNG, GZMK, and PDCD1 loci.

Goswami et al. analyzed the combined data from two clinical trials, CheckMate275 and IMvigor210, to determine the correlations of the AT-rich interactive domain containing protein 1A (ARID1A) mutations and CXCL13 expression with the patient's response to immune checkpoint blockade therapy [109] . CheckMate 275 is a phase 2 trial of nivolumab for the treatment of metastatic urothelial carcinoma (n = 265). IMvigor210 is a phase 2 trial of atezolizumab for the treatment of advanced or metastatic urothelial bladder cancer. They identified that an ARID1A mutation alone or CXCL13-high expression is correlated with favorable responses to ICI, and ARID1A mutation in combination with high levels of CXCL13 expression could predict the better response of patients to immune checkpoint blockade therapy than ARID1A mutation in combination with low levels of CXCL13 or high levels of CXCL13 in combination with ARID1A wild-type.

Thommen et al. classified CD8 + TILs derived from patients with NSCLC into three groups based on their PD-1 surface-level expression [34] . PD-1were CD8 + TILs without detectable PD-1 expression; PD-1 N were CD8 + TILs with PD-1 levels similar to those observed in healthy donors; PD-1 T were CD8 + TILs PD-1 with considerably high expression levels. The reactive capacity of PD-1 TILs was confirmed by co-culturing PD-1 T , PD-1 N , and PD-1 -, respectively, with autologous tumors isolated from eight patients. Among the eight patient-derived tumors, PD-1 T TILs showed strong reactivity against the tumor cells in 6 of 8 cultures. Gene expression diversity among PD-1 T , PD-1 N , and PD-1populations was identified by transcriptome analysis, which revealed that CXCL13 was one of the most upregulated genes in the PD-1 T subset. The authors used bead-based immunoassays to quantify inflammatory cytokine and chemokine levels in sorted PD-1 T TILs after 24h of culture, identifying that the levels of CXCL13 were the highest in the array. These data indicated that PD-1 T TILs are likely to secrete CXCL13 into the tumor microenvironment. Of 21 stage IV NSCLC patients receiving anti-PD-1 therapy, 7 patients were identified as responders, whereas the other 14 patients were identified as non-responders. Responders were characterized by TIL subsets with a higher percentage of PD-1 T TILs and total PD-1 T TIL cell numbers. Those with PD-1 T subsets > 1% of total cells were associated with longer median survival than those with PD-1 T subsets < 1% of total cells following the administration of anti-PD-1 therapy. IHC and digital image analysis suggested that PD-1 T TILs were localized in TLSs that formed both intratumorally and peritumorally. Intensive B cell marker staining and CD4 + T FH markers colocalized with PD-1 T TILs, implying that CD8 + PD-1 T TILs might recruit CXCR5 + B cells and T FH cells into the tumor region and that B cells, as well as T FH cells, could reinforce the antitumor capacity of CD8 + T cells.

Liver cancer is one of the world's most common cancers and the second leading cause of cancer deaths, and we also have some related studies in the past [125, 134, 135] . Hsu et al. established a platform to assess various biomarkers associated with prognostic efficacy for the immunotherapy response of patients with hepatocellular carcinoma (HCC) using Nanostring RNA analysis and multiplex immunofluorescence staining methods [125] . In this cohort, RNA was isolated from tumor samples before patients received anti-PD-1 or combination anti-PD-1 and anti-PD-L1 blockade therapy (n = 42). RNA was then hybridized to nCounter ® probes for the 770 predefined genes featured in the PanCancer Immune Profiling Panel. They found that exhausted CD8 + T cells were enriched in responders and analyzed exhausted CD8 + T cells using transcriptome analysis. In this Immune Profiling Panel, nine genes expressed on exhausted T cells were positively correlated with a better response to anti-PD-1 monotherapy or combination anti-PD-1 and anti-PD-L1 therapy, including CXCL13 gene expression. In another study, the exploratory analysis identified distinct gene signatures associated with tumor response and resistance to anti-PD-1 monotherapy in HCC patients also showed that CXCL13 was positively correlated with a better response to anti-PD-1 therapy [136] .

Litchfield et al. collected exome/transcriptome data from 12 cohorts, including 1008 patients who received immune checkpoint blockade therapy for the treatment of urothelial cancer (n = 387), melanoma (n = 353), head and neck cancer (n = 107), non-small cell lung cancer (n = 76), renal cell carcinoma (n = 51), colorectal cancer (n = 20), and breast cancer (n = 14) [132] . Immune checkpoint blockade could be classified into (1) anti-PD-1 (n = 432), (2) anti-PD-L1 (n = 421), and anti-CTLA4 (n = 155). The authors collected raw fastq sequencing data from these 12 cohorts and reprocessed them using a uniform bioinformatics pipeline. Next, they obtained clinical response data for participants in each of the 12 cohorts and reclassified them into complete response (CR)/partial response (PR) group versus stable disease (SD)/progressive disease (PD). Using the CPI1000+ database v1.1, they identified 101 genes that were significantly upregulated in CR/PR versus SD/PD, among which CXCL13 was the most upregulated gene among responders (CR/PR), suggesting that CXCL13 expression may be correlated with a patient's response to ICI therapy.

The incidence of ICI-induced mortality is estimated at about 0.3% to 1.3% [137] , and the risk is lower than conventional therapy, such as 0-4% with targeted therapies [138] and about 15% with allogeneic hematopoietic stem cell transplantation [139] . Different doses [140, 141] and the timing of administration and agents [142] may promote different levels of immune-related adverse events (irAEs) on patients receiving ICI. Common irAEs include headache, rash, pruritus, fatigue, pneumonitis, diarrhea, arthralgia, and endocrinopathies, which usually involve multiple organs [143] [144] [145] . Future research must address irAEs through more clinical trials, medical findings, and cutting-edge diagnosis tools, and the detailed mechanism causing these events will be better understood.

Two-thirds of CD8 + TILs express PD-1, and they mainly present an exhaustion situation [146] . ICI therapy is able to restore and enhance T cell function and effector cytokine production, such as TNF-α, IL-2, and IFN-γ [146] [147] [148] . Additionally, PD-1 inhibition could reverse the exhaustion status of specific T cells in tumor microenvironments [148] .

We summarize the previous findings examining the association between CXCL13/CXCR5 expression and the clinical response to tumor immunotherapy. CXCL13 expression was able to predict the response to ICI by directly or indirectly influencing the responses of various cancer types. However, the mechanism through which CXCL13/CXCR5 signaling induces the response of various immune subsets to ICI treatment remains unknown, and de-termining the cellular subsets that serve as the major producers of the CXCL13/CXCR5 signal that induces immune cell infiltration in cancer requires additional study.

The CXCL13/CXCR5 signaling axis is able to recruit immune cells and enhance the capacity to attack cancers. On the other hand, the CXCL13/CXCR5 axis may induce tumor development and facilitate the downregulation of T cell immunity due to associated immunosuppression cells infiltrating within the tumor microenvironment, such as MDSC [149] and T reg [150] . CXCL13/CXCR5 signaling forms two opposite influences for cancer development. When two distinct pathways have similar strengths, cancers maintain homeostasis. However, anti-PD-1 is able to enhance the function of T cells, strengthening their anti-tumor ability. Additionally, MDSC and T reg express PD-L1 [151] , and they may suppress T cell response by the PD-1/PD-L1 pathway. ICI therapy reduces immunosuppression and increases immune response, which is able to control tumor growth.

CXCL13 is a very important factor involved in the recruitment of CXCR5-producing immune cells to infiltrate the tumor microenvironment. CXCL13 expression was able to induce the establishment of TLS, which presents tumor antigens to T cells to determine consecutive T and B cell responses, resulting in the generation of effector T cells, plasma cells, and antibodies. In other words, the CXCL13/CXCR5 signal is able to turn "cold tumors" into "hot tumors". The ability of immunotherapy indicates an improved response, which activates lymphocyte function to kill cancer cells. The validation of the CXCL13/CXCR5 signaling pathway components as useful biomarkers for cancer diagnosis or prognosis, particularly the response to ICI, requires further investigation. Exploring the regulation of this pathway could provide an avenue for the design or more effective immunotherapy-based treatment strategies for cancer.

A guide to cancer immunotherapy: From T cell basic science to clinical practice

Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues

Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer

Precision Tumor Recognition by T Cells with Combinatorial Antigen-Sensing Circuits

Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention

Immune Cell Recruitment and Cell-Based System for Cancer Therapy

Uber die Entstehung der Entzundung und die entzundungerregeden Scadliekeiten

Chemotaxis in Leukocytes

Moving toward understanding eukaryotic chemotaxis

Editorial: The Role of Chemoattractants in the Tumor Microenvironment

A guide to chemokines and their receptors

Chemokines in homeostasis and diseases

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

T cell costimulation by chemokine receptors

The pros and cons of chemokines in tumor immunology

Cancer cell CCR2 orchestrates suppression of the adaptive immune response

-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression

Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response

The Biology of Chemokines and their Receptors

Chemokine Receptor Signaling and the Hallmarks of Cancer

CXCR7 Participates in CXCL12-mediated Cell Cycle and Proliferation Regulation in Mouse Neural Progenitor Cells

Protein-Coupled Chemokine Receptors Induce Both Survival and Apoptotic Signaling Pathways

The Chemokine Stromal Cell-Derived Factor-1 Promotes the Survival of Embryonic Retinal Ganglion Cells

CCL2 shapes macrophage polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-dependent gene expression profile

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy

A chemokine-driven positive feedback loop organizes lymphoid follicles

A Putative Chemokine Receptor, BLR1, Directs B Cell Migration to Defined Lymphoid Organs and Specific Anatomic Compartments of the Spleen

The Role of Chemokine and Glycosaminoglycan Interaction in Chemokine-Mediated Migration In Vitro and In Vivo

The CXCR5 Chemokine Receptor Is Expressed by Carcinoma Cells and Promotes Growth of Colon Carcinoma in the Liver

CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway

Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer

A transcriptionally and functionally distinct PD-1 + CD8 + T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

Dionysopoulos, D.; et al. The Role of CXCL13 and CXCL9 in Early Breast Cancer

CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer

Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis

Association of CXCL13 and Immune Cell Infiltration Signature in Clear Cell Renal Cell Carcinoma

Improved Outcome of High-Risk Early HER2 Positive Breast Cancer with High CXCL13-CXCR5 Messenger RNA Expression

CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis

Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer

Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma

Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway

Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer

Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts

CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment

Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice

CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma

Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors

Prigione, I.; Pistoia, V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow

Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis

Signal transduction by the chemokine receptor CXCR5: Structural requirements for G protein activation analyzed by chimeric CXCR1/CXCR5 molecules

Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5

Dynamic regulation of GDP binding to G proteins revealed by magnetic field-dependent NMR relaxation analyses

Rgs1 and Gnai2 Regulate the Entrance of B Lymphocytes into Lymph Nodes and B Cell Motility within Lymph Node Follicles

Impaired trafficking of Gnai2+/− and Gnai2−/− T lymphocytes: Implications for T cell movement within lymph nodes

Rho family GTPases and their regulators in lymphocytes

TNF-α and IL-10 Control CXCL13 Expression in Human Macrophages

IL-17 enhances the migration of B cells during asthma by inducing CXCL13 chemokine production in structural lung cells

The lymphotoxinβ receptor induces different patterns of gene expression via two NF-κB pathways

Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture

LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB

Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells

Bcl-6 is the nexus transcription factor of T follicular helper cells via repressor-of-repressor circuits

The opposing roles of the transcription factor E2A and its antagonist Id3 that orchestrate and enforce the naive fate of T cells

CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles

Follicular CD8+ T Cells: Origin, Function and Importance during HIV Infection

Id2 reinforces TH 1 differentiation and inhibits E2A to repress T FH differentiation

Bcl6 and Blimp-1 Are Reciprocal and Antagonistic Regulators of T Follicular Helper Cell Differentiation

TCF-1 at the Tfh and Th1 Divergence

Cutting Edge: Tcf1 Instructs T Follicular Helper Cell Differentiation by Repressing Blimp1 in Response to Acute Viral Infection

for the T Follicular Helper Cell Response to Viral Infection

LEF-1 and TCF-1 orchestrate T FH differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6

p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells

Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways

Inhibition of Gαi2 activation by Gαi3 in CXCR3-mediated signaling

Novel role of Giα2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells

RGS1 Is Expressed in Monocytes and Acts as a GTPase-activating Protein for G-protein-coupled Chemoattractant Receptors

B Cell-attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5

CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer

Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts

Cxc Chemokine Receptor 5 Expression Defines Follicular Homing T Cells with B Cell Helper Function

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer

CD4+ follicular helper T cell infiltration predicts breast cancer survival

Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like Transition

Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria

The lineage-defining factors T-bet and Bcl-6 collaborate to regulate Th1 gene expression patterns

The development and fate of follicular helper T cells defined by an IL-21 reporter mouse

Opposing Signals from the Bcl6 Transcription Factor and the Interleukin-2 Receptor Generate T Helper 1 Central and Effector Memory Cells

Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity

Bcl6 and Maf Cooperate to Instruct Human Follicular Helper CD4 T Cell Differentiation

Type I interferon induces CXCL13 to support ectopic germinal center formation

PD-1 blockade restores helper activity of tumor-infiltrating

Human Sox4 facilitates the development of CXCL13-producing helper T cells in inflammatory environments

A Transcriptionally Distinct CXCL13 + CD103 + CD8 + T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

CXCL13-mediated recruitment of intrahepatic CXCR5 + CD8 + T cells favors viral control in chronic HBV infection

CXCR5 and ICOS expression identifies a CD8 T-cell subset with T(FH) features in Hodgkin lymphomas

Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma

BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo

CXCL13 is a plasma biomarker of germinal center activity. Proc. Natl. Acad. Sci

The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13

Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers

Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer

Analysis of the Prognosis and Therapeutic Value of the CXC Chemokine Family in Head and Neck Squamous Cell Carcinoma

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer

Tumor-Associated Tertiary Lymphoid Structures: A Cancer Biomarker and a Target for Next-generation Immunotherapy

Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice

CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Immune checkpoint inhibitors: Recent progress and potential biomarkers

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner

TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma

Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma

Global Pattern of CD8 + T-Cell Infiltration and Exhaustion in Colorectal Cancer Predicts Cancer Immunotherapy Response

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

CD8 + T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression

Zebrafish as a disease model for studying human hepatocellular carcinoma

360 Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)

Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Management of Immune-Related Adverse Events and Kinetics of Response with Ipilimumab

Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies

CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer

Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer

Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1

Acknowledgments: This work was financially supported by the Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.

The authors declare no conflict of interest.